A phase II clinical trial is currently underway to evaluate the efficacy of combining Trametinib and AKT inhibitor GSK21411795 for the treatment of recurrent cervical cancer with PIK3CA and KRAS mutation 82. Here, KRAS is linked to cervical carcinoma.